Investing.com - Organogenesis Holdings (NASDAQ:ORGO) maintained its Buy rating and $9.00 price target at BTIG following an unexpected announcement from the Centers for Medicare & Medicaid Services ...
Medicare reimbursement issues expected for certain of Organogenesis' skin substitute projects disrupting revenues in 2025. Major catalyst is expected for ORGO with BLA filing in late 2025. Liquidity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results